Cover Image

Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition

Abstract

Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer - the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax' s Canvaxin, Aphton' s Insegia, Progenics' GMK vaccine, and Biomira' s Theratope. Despite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.

This Kalorama Information report - Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis - focuses on both preventive and therapeutic cancer vaccines in development. The following cancers for which there are vaccines in development or where there is a potential are profiled:

  • Cervical
  • Colon/Rectal
  • Lung
  • Lymphoma
  • Melanoma
  • Prostate
  • Breast
  • Gastrointestinal
  • Renal
  • Brain
  • Bladder
  • Ovarian
  • Leukemia

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there is current vaccines development are profiled. Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.

The report also includes current issues and trends affecting the industry.

This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.

Issues and trends discussed in The Emerging Cancer Vaccine Market include:

  • Early Detection and Screening
  • Monoclonal Antibodies and Therapeutic Vaccines
  • Safety Concerns
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine Strategies
  • Economic Conditions and Vaccine Discovery

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.

All market data pertains to the world market at the manufacturers' level. The years outlined in this study include projected markets for 2010 thru 2015. Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each vaccine segment covered. Competitive analysis is provided for the year 2015 for the developing and emerging market. The projected competitive analysis for 2015 was based on products in late stage development, probability of approval and marketing, and demographic trends.

Several companies have promising research and development activities for cancer vaccines. Additionally, many companies are in early stage development with a focused effort on providing favorable results in treating cancer. Many of these companies are:

  • Accentia
  • Antigenics
  • AVAX
  • Dendreon
  • GlaxoSmithKline
  • Merck & Co.
  • Northwest Biotherapeutics
  • Oncothyreon
  • Vaccinogen

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Disease Burden
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • Introduction
  • Cancer Descriptions
  • Timeline of Cancer Vaccine Developments
  • History and Growth of the Cancer Treatment Market
  • Types of Vaccines
    • Antigen/Adjuvant Vaccines
    • Whole Cell Tumor Vaccines
    • Dendritic Cell (DC) Vaccines
    • Viral Vectors and DNA Vaccines
    • Idiotype Vaccines
  • Types of Therapeutic Vaccines
    • Patient-Specific Vaccines
    • Prostate Specific Antigen
    • Sialyl Tn
    • Heat Shock Proteins
    • Ganglioside Molecules
    • Carcinoembryonic Antigen (CEA)
    • MART-1
    • Tyrosinase
    • Adjuvants
  • Industry Structure
  • Demographics and Statistics
    • Growing and Aging Population
  • Tobacco Use and Obesity Increases Cancer Risk
    • Tobacco Use
    • Obesity
    • Life Expectancy and Cancer

CHAPTER THREE: CERVICAL CANCER VACCINES

  • Overview
  • Description of Vaccines on the Market
    • Gardasil/Silgard
    • Cervarix
  • Description of Vaccines in Development
    • V503
    • RG3484
    • PV701
    • Lovaxin C
    • VGX-3100
    • CA-9
  • Market Summary
  • Current and Potential Competitors and Analysis, 2015

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

  • Overview
  • Description of Vaccines on the Market
    • OncoVAX
  • Description of Vaccines in Development
    • OncoVAX
    • TroVAX
    • CEA VRP Vaccine (AVX701)
    • IMA910
    • CDX-1307
    • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
    • MKC1106-PP
    • GI-4000
    • GVAX
    • Oncophage
    • CRS-207
    • Lapuleucel-T
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER FIVE: LUNG CANCER VACCINES

  • Overview
  • Description of Vaccines in Development
    • Lucanix
    • MAGE-A3 Peptide
    • Stimuvax
    • EGF Cancer Vaccine
    • HyperAcute Lung
    • GI-4000
    • Oncophage
    • TG 4010
    • LungVAX
    • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
    • DCVax-Lung
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER SIX: LYMPHOMA VACCINES

  • Overview
  • Description of Vaccines in Development
  • BiovaxID
  • MyVax
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER SEVEN: MELANOMA VACCINES

  • Overview
  • Description of Vaccines on the Market
  • Description of Vaccines in Development
  • MVAX
  • Allovectin-7
  • MDX-1379 with Combination Treatment MDX-010
  • Oncophage
  • MAGE-A3 ASCI
  • ALVAC Vaccine
  • HyperAcute Melanoma
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER EIGHT: PROSTATE CANCER VACCINES

  • Overview
  • Description of Vaccines on the Market
  • Provenge
  • Description of Vaccines in Development
  • DCVax-Prostate
  • GVAX
  • PROSTVAC-VF
  • TroVAX
  • Onyvax-P
  • MVA-BN Prostate
  • HyperAcute Prostate
  • NeuVax
  • MKC1106-PP
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER NINE: BREAST CANCER VACCINES

  • Overview
  • Description of Vaccines in Development
  • Stimuvax
  • NeuVax
  • GVAX
  • AVX701 Vaccine
  • MVA-BN HER2
  • Lapuleucel-T
  • CDX-1307-02
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
  • Market Summary

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

  • Overview
  • Description of Vaccines in Development
  • GI-4000
  • HyperAcute Pancreas
  • GVAX
  • Oncophage
  • CDX-1307
  • ANZ-100
  • DCVax
  • Market Summary

CHAPTER ELEVEN: RENAL CANCER VACCINES

  • Overview
  • Description of Vaccines on the Market
  • Oncophage
  • Description of Vaccines in Development
  • Oncophage
  • Reniale
  • TroVAX
  • IMA901
  • AGS-003
  • MDX-1106
  • MKC1106-PP
  • Market Summary
  • Potential Competitors and Analysis, 2015

CHAPTER TWELVE: BRAIN CANCER VACCINES

  • Overview
  • Glioblastoma
  • Neuroblastoma
  • Description of Vaccines in Development
  • DCVax-Brain
  • CDX-110
  • GliaAtak
  • Oncophage
  • Market Summary

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

  • Overview
  • Description of Vaccines on the Market
  • BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-
  • Shire Pharmaceuticals)
  • Description of Vaccines in Development
  • CDX-1307
  • Market Summary

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

  • Overview
  • Description of Vaccines in Development
  • Abagovomab
  • OVax Autologous Cell Vaccine
  • Lapuleucel-T
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
  • Market Summary

CHAPTER FIFTEEN: LEUKEMIA VACCINES

  • Overview
  • Description of Vaccines in Development
  • GVAX-Leukemia
  • GRNVAC1
  • PR1 Peptide Vaccine
  • Market Summary

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

  • Introduction
  • Early Detection and Screening
  • Monoclonal Antibodies and Therapeutic Vaccines
  • Political and Social Pressure
  • Safety Concerns
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine Strategies
  • Economic Conditions Affect Investing in Some Cancer Vaccine Discovery

CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS

  • Overview
  • Total Market Size and Forecast
  • Prophylactic versus Therapeutic Cancer Vaccine Market Size
  • Market and Competitor Analysis

CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES

  • Introduction
  • Accentia Biopharmaceuticals, Inc.
  • Antigenics, Inc.
  • Avax Technologies, Inc.
  • Dendreon Corporation
  • GlaxoSmithKline plc
  • Merck & Company, Inc.
  • Northwest Biotherapeutics, Inc.
  • Oncothyreon, Inc
  • Vaccinogen, Inc.

APPENDIX: COMPANY NAMES AND ADDRESSES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
  • Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
  • Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015

CHAPTER TWO: INTRODUCTION

  • Table 2- Significant Cancer Vaccine Approvals, 2000-201
  • Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexe
  • Figure 2-1 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
  • Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
  • Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
  • Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
  • Figure 2-3 World Population by Selected Geographical Region, 2010-2050
  • Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050
  • Figure 2-4 Estimated World Population by Age, 2010 and 2050
  • Table 2-6 Percent of Smokers by Country
  • Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
  • Table 2-7 Estimated Obesity by Country 2009 Estimates
  • Figure 2-6 Estimated Obesity by Country as a Portion of Total Population 2009 Estimates
  • Figure 2-7 Increases in Obesity by Country - 2007 and 2009 Figures
  • Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
  • Figure 2-8 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2006
  • Figure 2-9 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
  • Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of Death, All Races, Both Sexes, 2006

CERVICAL CANCER VACCINES

  • Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
  • Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
  • Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline
  • Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
  • Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
  • Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015

COLON/RECTAL CANCER VACCINES

  • Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
  • Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
  • Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline

LUNG CANCER VACCINES

  • Table 5-1 TYPES OF PRIMARY LUNG CANCER
  • Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
  • Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
  • Table 5-3 Lung Cancer Vaccines in the Pipeline

LYMPHOMA VACCINES

  • Table 6-1 CLASSIFICATION OF NON-HODGKIN' S LYMPHOMAS
  • Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
  • Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
  • Table 6-3 Lymphoma Vaccines in the Pipeline

MELANOMA VACCINES

  • Table 7-1 MALIGNANT CONDITIONS OF THE SKIN
  • Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
  • Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
  • Table 7-3 Melanoma Vaccines in the Pipeline
  • Table 7-3 (continued) Melanoma Vaccines in the Pipeline
  • Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
  • Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
  • Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines, 2007-2015

PROSTATE CANCER VACCINES

  • Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
  • Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
  • Table 8-2 Prostate Cancer Vaccines in the Pipeline
  • Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline
  • Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
  • Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
  • Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
  • Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2015

BREAST CANCER VACCINES

  • Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
  • Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
  • Table 9-2 Breast Cancer Vaccines in the Pipeline

GASTROINTESTINAL CANCER VACCINES

  • Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
  • Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
  • Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline

RENAL CANCER VACCINES

  • Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
  • Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
  • Table 11-2 Renal Cancer Vaccines in the Pipeline

BRAIN CANCER VACCINES

  • Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
  • Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
  • Table 12-2 Brain Cancer Vaccines in the Pipeline

BLADDER CANCER VACCINES

  • Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
  • Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
  • Table 13-2 Bladder Cancer Vaccines in the Pipeline

OVARIAN CANCER VACCINES

  • Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
  • Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
  • Table 14-2 Ovarian Cancer Vaccines in the Pipeline

LEUKEMIA VACCINES

  • Table 15-1 TYPES OF LEUKEMIA
  • Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
  • Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
  • Table 15-3 Leukemia Vaccines in the Pipeline

ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

  • Table 16-1 Cancer Detection Tests
  • Table 16-2 Early Safety Statistics Concerning HPV Vaccination

THE CANCER VACCINE MARKET: MARKET FORECASTS

  • Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
  • Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
  • Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
  • Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets, 2007-2015 208
  • Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets by Percent, 2015

CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES

Show More
Pricing
Get Notified
Email me when related reports are published